Silo Pharma, Inc.
SILO
$0.39
$0.023.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | 1,280.00% | 1,280.00% | 1,280.00% | 0.00% | 0.00% |
| Gross Profit | -116.27% | -116.27% | -116.27% | 0.00% | 0.00% |
| SG&A Expenses | 12.00% | -36.63% | 18.88% | -12.55% | -10.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.01% | -56.07% | 13.75% | 24.08% | 23.91% |
| Operating Income | -45.75% | 56.63% | -14.00% | -24.51% | -24.40% |
| Income Before Tax | -59.70% | 49.06% | -19.55% | -29.24% | -28.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.70% | 49.06% | -19.55% | -29.24% | -28.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.70% | 49.06% | -19.55% | -29.24% | -28.65% |
| EBIT | -45.75% | 56.63% | -14.00% | -24.51% | -24.40% |
| EBITDA | -45.89% | 56.71% | -13.83% | -- | -- |
| EPS Basic | 47.78% | 82.90% | 44.88% | 37.16% | 17.74% |
| Normalized Basic EPS | 47.99% | 82.98% | 44.85% | 37.01% | 17.51% |
| EPS Diluted | 47.78% | 82.90% | 44.88% | 37.16% | 17.74% |
| Normalized Diluted EPS | 47.99% | 82.98% | 44.85% | 37.01% | 17.51% |
| Average Basic Shares Outstanding | 205.70% | 197.96% | 116.92% | 105.71% | 56.42% |
| Average Diluted Shares Outstanding | 205.70% | 197.96% | 116.92% | 105.71% | 56.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |